NEXGEL Hires Sales Leader Who Generated $50M Biologics Revenue for BIONX Surgical
Dave Hazard joins NEXGEL as Vice President of Sales for its newly formed BIONX Surgical division, bringing over 13 years of orthobiologics leadership and a track record of building a 400-representative salesforce. He expanded Arthrex's biologics business, generating over $50 million in revenue and securing Smith+Nephew as a white-label partner.
1. Appointment Details
NEXGEL has appointed Dave Hazard as Vice President of Sales for its newly launched BIONX Surgical division, formed through a recent acquisition aimed at scaling the company's surgical revenue. Hazard will lead the division's commercialization efforts and build a scalable sales infrastructure to drive enterprise partnerships and repeatable revenue streams.
2. Hazard's Industry Background
Hazard brings over 13 years of sales leadership in orthopedics, spine and biologics, including four years at Nuo Therapeutics where he built a 400-representative salesforce and secured Smith+Nephew as a white-label partner. At Arthrex, he expanded an orthobiologics unit to generate more than $50 million in annual revenue across orthopedic and sports medicine specialties.
3. Commercial Growth Outlook
The BIONX Surgical division is positioned to leverage a pipeline of tissue and hydrogel products across sports medicine, orthopedics, plastics and wound care. Hazard's expertise in strategic partnerships and high-performing team development is expected to accelerate market adoption and contribute meaningfully to NEXGEL's overall revenue growth.